Multi-Drug Therapies Vastly Reduce China Leprosy, But Thousands Remain
This article was originally published in PharmAsia News
Executive Summary
Leprosy has yet to be eradicated in China, particularly in 10 percent of the country, despite long-term efforts by the country and multi-drug therapies introduced in the 1980s. The secretary-general of the China Leprosy Association said about 1,600 new cases are reported every year, two percent of them children. The disease is no longer considered a public health threat, but the Ministry of Health estimates there are still 6,300 leprosy patients in the country. China counted 500,000 cases in 1949. (Click here for more
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.